

# Product Datasheet

## HSD17B13 Antibody - Azide and BSA Free NBP3-04837-100ul

Unit Size: 100 ul

Store at -20C. Avoid freeze-thaw cycles.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NBP3-04837](http://www.novusbio.com/NBP3-04837)

Updated 2/17/2026 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NBP3-04837](http://www.novusbio.com/reviews/destination/NBP3-04837)



**NBP3-04837-100ul**

HSD17B13 Antibody - Azide and BSA Free


Product Information	
Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.3), 50% glycerol
Target Molecular Weight	34 kDa

Product Description	
Description	Novus Biologicals Rabbit HSD17B13 Antibody - Azide and BSA Free (NBP3-04837) is a polyclonal antibody validated for use in IHC, WB, ELISA and ICC/IF. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	345275
Gene Symbol	HSD17B13
Species	Human, Mouse, Rat
Immunogen	Recombinant fusion protein containing a sequence corresponding to amino acids 30-211 of human HSD17B13 (NP_835236.2). RRKSVAGEIVLITGAGHGIGRQTTYEFAKRQSILVLWDINKRGVEETAECRKLG VTAHAYVVDCSNREEIYRSLNQVKKEVGDVTIVVNNAGTVYPADLLSTKDEEIT KTFEVNILGHFWITKALLPSMMERNHGHIVTVASVCGHEGIPYLIPYCSSKFAAV GFHRGLTSELQALGKTGI


Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 1:500 - 1:1000, ELISA Recommended starting concentration is 1 µg/mL, Immunohistochemistry 1:50 - 1:200, Immunocytochemistry/Immunofluorescence 1:50 - 1:200, Immunohistochemistry-Paraffin 1:50 - 1:200

**Images**


Western Blot: HSD17B13 Antibody [NBP3-04837] - Analysis of extracts of various cell lines, using HSD17B13 antibody at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 180s.




Immunohistochemistry-Paraffin: HSD17B13 Antibody [NBP3-04837] - Human liver cancer using HSD17B13 Rabbit pAb at dilution of 1:100 (40x lens). High pressure antigen retrieval performed with 0.01M Citrate Buffer (pH 6.0) prior to IHC staining.




Immunohistochemistry-Paraffin: HSD17B13 Antibody [NBP3-04837] - Human liver using HSD17B13 Rabbit pAb at dilution of 1:100 (40x lens). High pressure antigen retrieval performed with 0.01M Citrate Buffer (pH 6.0) prior to IHC staining.




Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded human liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.




Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded rat liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.




Immunocytochemistry/ Immunofluorescence: HSD17B13 Antibody - Azide and BSA Free [HSD17B13] - Immunofluorescence analysis of paraffin-embedded mouse liver using HSD17B13 Rabbit pAb at dilution of 1:20 (40x lens). Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.




HSD17B13 promotes the accumulation of intracellular lipid droplets and causes hepatocyte injury. (A) mRNAs in palmitate-treated cells were measured by qRT-PCR. (B) Schematic of full-length or truncated transcripts of HSD17B13. (C) Representative confocal images of L02 cells transfected with His-tagged HSD17B13 transcripts (red) and LDs (green) after being induced by OA (400  $\mu$ M) for 24 h. Nuclei were labeled with DAPI (blue). (D,E) Representative immunofluorescence staining images for LDs (red) (D) and relative intracellular Nile red positive areas were quantified (E) in L02 cells transfected with HSD17B13 transcripts after OA (400  $\mu$ M) challenge for 24 h, the slides were counterstained with DAPI. (F) Schematic of the experimental design for investigating the effect of HSD17B13 on intracellular TGs, the contents of TGs were detected and the half-life of TGs was calculated. (G,H) Levels of ALT (G) and AST (H) in supernatants and cell lysates of Huh7 cells transfected with the plasmids of HSD17B13 for 24 h. (I) mRNA of proinflammatory markers in L02 cells transfected with plasmids of HSD17B13 for 24 h. Results are expressed as mean  $\pm$  SEM. OA, oleic acid; LDs, lipid droplets; TGs, triglycerides; PLIN2, perilipin 2; ALT, alanine transaminase; AST, aspartate transaminase; TGF- $\beta$ 1, transforming growth factor-beta 1; IL-6, interleukin 6; CXCL3, C-X-C motif chemokine ligand 3. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Higher HSD17B13 expression is mainly in hepatocytes and directly induced by etiological agents. (A,B) Protein (A) and mRNA (B) were detected in mouse primary cells. (C) Liver samples from NAFLD mice induced by HFD, BDL, CCl<sub>4</sub>, and MCD were processed with immunofluorescence co-staining for HSD17B13 with ALB (hepatocyte marker), CD31 (endothelial marker),  $\alpha$ -SMA (activated HSC marker), or CD11b (macrophage marker). Slides were counterstained with DAPI (Scale bars, 50  $\mu$ m). (D) L02 cells were treated by palmitate, OA, CCl<sub>4</sub> lipopolysaccharide, or TGF- $\beta$ 1 for 24 h, mRNA was measured by qRT-PCR. (E,F) Huh7.5 cells were infected with HCV, RNAs were measured by qRT-PCR (E), and proteins were measured by Western blotting (F) at 72 h. (G) Huh7.5 cells were infected by HCV (MOI = 0.1) and mRNA was measured by qRT-PCR at designated days post-infection. (H) mRNA in respective host cells infected by HCV, H1N1 and EV71 was measured by qRT-PCR. Results are expressed as mean  $\pm$  SEM. HSCs, hepatic stellate cells; KCs, Kupffer cells; LSECs, liver sinusoidal endothelial cells; PHs, hepatic parenchymal cells; HFD, high-fat diet; BDL, bile-duct ligation; CCl<sub>4</sub>, carbon tetrachloride; MCD, methionine-choline-deficient diet; OA, oleic acid; TGF- $\beta$ 1, transforming growth factor-beta 1; MOI, multiplicity of infection; HCV, hepatitis C virus; H1N1, influenza A virus; EV71, enterovirus type 71. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean  $\pm$  SEM. (scale bars, 50  $\mu$ m). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl<sub>4</sub>, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean  $\pm$  SEM. (scale bars, 50  $\mu$ m). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl<sub>4</sub>, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



HSD17B13 promotes the accumulation of intracellular lipid droplets and causes hepatocyte injury. (A) mRNAs in palmitate-treated cells were measured by qRT-PCR. (B) Schematic of full-length or truncated transcripts of HSD17B13. (C) Representative confocal images of L02 cells transfected with His-tagged HSD17B13 transcripts (red) and LDs (green) after being induced by OA (400  $\mu$ M) for 24 h. Nuclei were labeled with DAPI (blue). (D,E) Representative immunofluorescence staining images for LDs (red) (D) and relative intracellular Nile red positive areas were quantified (E) in L02 cells transfected with HSD17B13 transcripts after OA (400  $\mu$ M) challenge for 24 h, the slides were counterstained with DAPI. (F) Schematic of the experimental design for investigating the effect of HSD17B13 on intracellular TGs, the contents of TGs were detected and the half-life of TGs was calculated. (G,H) Levels of ALT (G) and AST (H) in supernatants and cell lysates of Huh7 cells transfected with the plasmids of HSD17B13 for 24 h. (I) mRNA of proinflammatory markers in L02 cells transfected with plasmids of HSD17B13 for 24 h. Results are expressed as mean  $\pm$  SEM. OA, oleic acid; LDs, lipid droplets; TGs, triglycerides; PLIN2, perilipin 2; ALT, alanine transaminase; AST, aspartate transaminase; TGF- $\beta$ 1, transforming growth factor-beta 1; IL-6, interleukin 6; CXCL3, C-X-C motif chemokine ligand 3. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



HSD17B13 expression is increased in the liver tissues of patients and murine models with NAFLD. (A–C) Representative H&E and immunohistochemical staining and the statistical summary in a human liver tissue array (A), the results were re-distinguished between man and woman (B), the results were re-distinguished with or without HBV infection (C). (D) C57BL/6 mice or SD rats were treated with pathogenic agents accordingly. Representative H&E and immunohistochemical staining of the murine livers. (E,F) mRNA (E) and protein (F) in the murine livers were measured by qRT-PCR and Western blotting, respectively. Results are expressed as mean  $\pm$  SEM. (scale bars, 50  $\mu$ m). NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; MCD, methionine choline deficient diet; CDHFD, choline deficient and high-fat diet; HFD, high-fat diet; DEN, diethylnitrosamine; CCl<sub>4</sub>, carbon tetrachloride; BDL, bile-duct ligation. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35628360>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NBP3-04837-100ul**

---

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NBP3-04837](http://www.novusbio.com/reviews/submit/NBP3-04837)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

